Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Gross Margin (2016 - 2025)

Ptc Therapeutics has reported Gross Margin over the past 10 years, most recently at 95.78% for Q4 2025.

  • Quarterly results put Gross Margin at 95.78% for Q4 2025, up 342.0% from a year ago — trailing twelve months through Dec 2025 was 97.28% (up 654.0% YoY), and the annual figure for FY2025 was 97.28%, up 440.0%.
  • Gross Margin for Q4 2025 was 95.78% at Ptc Therapeutics, up from 92.52% in the prior quarter.
  • Over the last five years, Gross Margin for PTCT hit a ceiling of 98.91% in Q1 2025 and a floor of 90.52% in Q4 2023.
  • Median Gross Margin over the past 5 years was 93.62% (2025), compared with a mean of 93.89%.
  • Biggest five-year swings in Gross Margin: tumbled -298bps in 2023 and later surged 592bps in 2025.
  • Ptc Therapeutics' Gross Margin stood at 94.36% in 2021, then dropped by -1bps to 93.49% in 2022, then fell by -3bps to 90.52% in 2023, then increased by 2bps to 92.36% in 2024, then rose by 4bps to 95.78% in 2025.
  • The last three reported values for Gross Margin were 95.78% (Q4 2025), 92.52% (Q3 2025), and 93.62% (Q2 2025) per Business Quant data.